Prostate Cancer

Grade, stage, and risk group — how prostate cancer is classified, and why active surveillance is often the right answer.

The most important thing to understand

Prostate cancer covers an enormously wide range of behavior. Some are so slow-growing they will never threaten a man's life; others are genuinely aggressive and need prompt treatment. Two men can carry the same diagnosis and need entirely different management.

So the first task after diagnosis is not choosing a treatment — it is establishing which kind you have.

Grade group and Gleason score

The pathologist grades the cancer by how abnormal the cells appear, reported as a Gleason score and a Grade Group from 1 to 5.

Grade Group 1 (Gleason 6) is very low risk and essentially never spreads. Grade Group 2 (3+4=7) is favorable intermediate. Grade Group 3 (4+3=7) is unfavorable intermediate. Grade Groups 4 and 5 (Gleason 8-10) are high risk.

Note that 3+4 and 4+3 both total 7 but behave differently — the first number is the predominant pattern, and it matters.

Staging and risk grouping

Stage describes extent: confined to the prostate, extending beyond the capsule, or spread to lymph nodes or bone. Grade, stage, and PSA are combined into a risk group — very low, low, intermediate, or high — which is what actually guides treatment.

Imaging is not needed for low-risk disease. For higher-risk cancers we may obtain bone imaging, CT, or a PSMA PET scan, which is considerably more sensitive than older studies.

Active surveillance

For low-risk disease, the preferred approach for most men is active surveillance — monitoring closely with periodic PSA, exams, MRI, and repeat biopsy, and treating only if the cancer shows signs of progression.

This is not neglect, and it is not the same as doing nothing. It is a deliberate strategy that avoids the side effects of treatment in men whose cancer is unlikely to ever harm them, while keeping treatment fully available if the situation changes. Most men on surveillance never require treatment. Many who do are still cured.

Treatment options

Radical prostatectomy removes the prostate, usually robotically. The main trade-offs are urinary incontinence, which typically improves substantially over months, and erectile dysfunction, which depends heavily on nerve preservation, your age, and your function beforehand.

Radiation therapy — external beam or brachytherapy — is comparably effective for localized disease. Its side effect profile differs: less immediate incontinence, more bowel and bladder irritation, and erectile function that tends to decline more gradually.

Hormone therapy lowers testosterone and is used with radiation for higher-risk disease, or for advanced cancer. Focal therapy treats only part of the gland and is appropriate in selected cases.

For localized disease, surgery and radiation produce similar long-term survival. The choice legitimately rests on side effect profiles, your other medical conditions, and your own preferences.